<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00698607</url>
  </required_header>
  <id_info>
    <org_study_id>EXCELLENT</org_study_id>
    <nct_id>NCT00698607</nct_id>
  </id_info>
  <brief_title>Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing</brief_title>
  <acronym>EXCELLENT</acronym>
  <official_title>Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives

        1. To evaluate the safety and long-term effectiveness of coronary stenting with the
           Everolimus-eluting coronary stent system(EECSS) (XIENCETM V, Abbott Vascular, Santa
           Clara, CA, PromusTM, Boston Scientific, Natick, MA), compared with the sirolimus-eluting
           coronary stent system(SECSS) (CypherTM, Cordis Johnson &amp; Johnson, Warren, NJ) in the
           treatment of coronary stenosis.

        2. To evaluate the safety and efficacy of 6-month clopidogrel therapy compared with
           12-month clopidogrel therapy.

      Study Design: Prospective, open label, two-arm, randomized multi-center trial to test the
      non-inferiority of EECSS compared with the SECSS, and to test the non-inferiority of 6 months
      duration compared with 12 months duration of clopidogrel therapy. Patients will be randomized
      in a two by two factorial manner according to the type of drug eluting stent (EECSS vs.
      SECSS) and the duration of dual anti-platelet therapy (6 months vs. 12 months). Randomization
      will also be stratified per hospital for the presence of DM and the presence of long lesions
      (lesion length â‰¥ 28mm)

      Patient Enrollment: 1,372 patients enrolled at 17 centers in Korea.

      Patient Follow-Up: Clinical follow-up will occur at 1, 3, and 9 months, and at 1, 2, 3, 4,
      and 5 years. Investigator or designee may conduct follow-up as telephone contacts or office
      visits.

      Primary Endpoint

        -  In-segment late luminal loss (LL) at 9 months for comparison of stenting with EECSS vs.
           SECSS.

        -  Target vessel failure (TVF) (cardiac death, myocardial infarction, ischemia driven
           target vessel revascularization) at 12 months for comparison of 6 months vs. 12 months
           of clopidogrel therapy

      Secondary Endpoint

        -  All Death

        -  Cardiac death

        -  Myocardial infarction

        -  Target vessel revascularization (TVR) (all and ischemia-driven)

        -  Target lesion revascularization (TLR) (all and ischemia-driven)

        -  Stent thrombosis

        -  Acute success (device, lesion, and procedure)

        -  Bleeding

        -  Cerebrovascular accident

        -  In-stent LL at 9 months

        -  Angiographic pattern of restenosis at 9-month angiographic follow-up

        -  In-stent and in-segment % diameter stenosis (%DS) at 9 months

        -  In-stent % volume obstruction (%VO) at 9 months

        -  Incomplete stent apposition post index procedure

        -  Persisting incomplete stent apposition, late-acquired incomplete stent apposition,
           aneurysm, thrombosis, and persisting dissection at 9 months
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-segment late luminal loss (LL) at 9 months for comparison of stenting with EECSS vs. SECSS.</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Target vessel failure (TVF) (cardiac death, myocardial infarction, ischemia driven target vessel revascularization) at 12 months for comparison of 6 months vs. 12 months of clopidogrel therapy</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All death</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>5 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (TVR) (all and ischemia-driven)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (TLR) (all and ischemia-driven)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute success (device, lesion, and procedure)</measure>
    <time_frame>Index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular accident</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent LL at 9 months</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic pattern of restenosis at 9-month angiographic follow-up</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment % diameter stenosis (%DS) at 9 months</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent % volume obstruction (%VO) at 9 months</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incomplete stent apposition post index procedure</measure>
    <time_frame>Index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persisting incomplete stent apposition, late-acquired incomplete stent apposition, aneurysm, thrombosis, and persisting dissection at 9 months</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1466</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>E6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus-eluting stent 6-month clopidogrel therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sirolimus-eluting stent 6-month clopidogrel therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus-eluting stent 12-month clopidogrel therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S12</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sirolimus-eluting stent 12-month clopidogrel therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Everolimus-eluting stent (Xience or Promus)</intervention_name>
    <description>Use everolimus-eluting stent in the treatment of coronary stenosis</description>
    <arm_group_label>E6</arm_group_label>
    <arm_group_label>E12</arm_group_label>
    <other_name>Xience</other_name>
    <other_name>Promus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus-eluting stent (Cypher)</intervention_name>
    <description>Use sirolimus-eluting stent in the treatment of coronary stenosis</description>
    <arm_group_label>S6</arm_group_label>
    <arm_group_label>S12</arm_group_label>
    <other_name>Cypher</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6-month clopidogrel therapy</intervention_name>
    <description>Use clopidogrel for 6 months</description>
    <arm_group_label>E6</arm_group_label>
    <arm_group_label>S6</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12-month clopidogrel therapy</intervention_name>
    <description>Use clopidogrel for 12 months</description>
    <arm_group_label>E12</arm_group_label>
    <arm_group_label>S12</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:

          1. Subject must be at least 18 years of age.

          2. Subject is able to verbally confirm understandings of risks, benefits and treatment
             alternatives of receiving the XIENCE V EECS and he/she or his/her legally authorized
             representative provides written informed consent prior to any study related procedure.

          3. Subject must have significant coronary artery stenosis (&gt;50% by visual estimate)

          4. Subject must have evidence of myocardial ischemia (e.g., stable, unstable angina,
             recent infarction, silent ischemia, positive functional study or a reversible changes
             in the electrocardiogram (ECG) consistent with ischemia. In subjects with coronary
             artery stenosis &gt; 75%, evidence of myocardial ischemia does not have to be documented.

          5. Subjects must be an acceptable candidate for Coronary Artery Bypass Graft (CABG)
             surgery.

        Angiographically Inclusion Criteria

          1. Target lesion(s) must be located in a native coronary artery with visually estimated
             diameter of â‰¥ 2.25 mm and â‰¤ 4.25 mm.

          2. Target lesion(s) must be amenable for percutaneous coronary intervention

        General Exclusion Criteria:

          1. The patient has a known hypersensitivity or contraindication to any of the following
             medications (heparin, aspirin, clopidogrel, sirolimus, everolimus, Contrast media

          2. Systemic (intravenous) Sirolimus, everolimus use within 12 months.

          3. Female of childbearing potential, unless a recent pregnancy test is negative, who
             possibly plan to become pregnant any time after enrollment into this study.

          4. History of bleeding diathesis or known coagulopathy (including heparin-induced
             thrombocytopenia), or will refuse blood transfusions.

          5. Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery
             within 2 months.

          6. Current known current platelet count &lt;100,000 cells/mm3 or Hgb &lt;10 g/dL.

          7. An elective surgical procedure is planned that would necessitate interruption of
             clopidogrel during the first 12 months post enrollment.

          8. Non-cardiac co-morbid conditions are present with life expectancy &lt;1 year or that may
             result in protocol non-compliance (per site investigator's medical judgment).

          9. Patients who are actively participating in another drug or device investigational
             study, which have not completed the primary endpoint follow-up period.

         10. Patients who have received any stent implantation in the target vessel prior to
             enrollment.

         11. Patients with LVEF&lt;25% or those with cardiogenic shock

         12. Patients with myocardial infarction within 72 hours

         13. Creatinine level â‰¥ 3.0mg/dL or dependence on dialysis.

         14. Severe hepatic dysfunction (AST and ALT: 3 times upper normal reference values).

        Angiographic Exclusion Criteria

          1. Patients with significant left main coronary artery stenosis

          2. Patients who's target lesion has in-stent restenosis at the stented segment of
             drug-eluting stents or bare metal stents

          3. Target lesions with chronic total occlusion

          4. True bifurcation lesions requiring two stents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo-Soo Kim, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yangsoo Jang, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jung-Han Yoon, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Yonsei Univercity Wonju hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahn Tae-Hoon, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Gachon Kil Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyun-Cheol Kwon, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>In-Ho Chae, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young-Jin Choi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kyoo-Rok Han, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kandong Sacred heart Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Si-Hoon Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ewha Women's University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myeong-Ho Chung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyuk-Moon Kwon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dong-Woon Chun, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Health Insurance Service Ilsan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Byung-Ok Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University Sanggye Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Do-Sun Lim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Taek-Jong Hong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Woo-Young Chung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Borame Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jae-Hun Chung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Kangnam Sacred Heart Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>28 Yongon Dong, Jongro Gu</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2008</study_first_submitted>
  <study_first_submitted_qc>June 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2008</study_first_posted>
  <last_update_submitted>June 28, 2010</last_update_submitted>
  <last_update_submitted_qc>June 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hyo-Soo, Kim</name_title>
    <organization>Seoul National University Hospital</organization>
  </responsible_party>
  <keyword>Everolimus</keyword>
  <keyword>Sirolimus</keyword>
  <keyword>drug eluting stent</keyword>
  <keyword>Clopidogrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

